FDA’s Woodcock highlights gaps in knowledge about Chinese APIs, promotes advanced manufacturing to bolster U.S. security

A congressional hearing Wednesday on safeguarding pharmaceutical supply chains will focus on concerns that reliance on Chinese APIs threatens U.S. national security and creates health risks for American patients.

The House Energy and Commerce Committee’s health subcommittee will hear that concerns about drug supply chains originating in or running through China are exacerbated by a lack of information.

In testimony released in advance of

Read the full 639 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers